menu search

Cidara therapeutics and mundipharma receive positive chmp opinion for rezafungin for the treatment of invasive candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and e...

October 13, 2023, 2:34 pm

Scynexis: a disappointing q1 earnings and cooling gsk catalyst - we maintain neutral rating

SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. P...

May 19, 2023, 4:57 pm

Scynexis (scyx) inks antifungal drug deal with gsk

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also contin...

March 31, 2023, 1:47 pm

Scynexis: licensing deal with gsk, upgrading to a hold rating from a sell

GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal ...

March 31, 2023, 11:47 am

Why is scynexis (scyx) stock up 69% today?

Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an ...

March 30, 2023, 10:26 am

Why is cidara therapeutics (cdtx) stock down 12% today?

Cidara Therapeutics (NASDAQ: CDTX ) stock is falling on Thursday despite the immunotherapy company getting positive news from the FDA. The big FDA new...

March 23, 2023, 9:16 am

Vulvovaginal candidiasis treatment market is likely to witness steady growth, anticipated to reach us$ 1607 million by 2033: future market insights, inc.

The vulvovaginal candidiasis treatment market is exploding, expected to skyrocket from its current US$1...

January 17, 2023, 5:30 am


Search within

Pages Search Results: